Vor Biopharma Inc

VOR | $1.74 -7.45% -7.74% 290K

(0.0% 1d) (-19.4% 1m) (-60.9% 1y) (0.0% 2d) (-7.4% 3d) (1.8% 7d) (-100.0% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 118,695,442
https://www.vorbiopharma.com
Sec Filling | Patents | 88 employees

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

ceiling cancer treatment t-cell

add to watch list Paper trade email alert is off

Press-releases

PureTech Announces Annual Results for Year Ended December 31, 2023
Published: 2024-04-25 (Just crawled : 11:00) - biospace.com/
KRTX | $329.83 0.0% 1.9M

Health Technology

| Email alert Add to watchlist
BMY | $48.86 -0.27% 0.98% 14M

Health Technology

| Email alert Add to watchlist
VOR | $1.74 -7.45% -7.74% 290K

| Email alert Add to watchlist
FNCTF | News | $11.16 1.13% -20.84% 0

Communications

| Email alert Add to watchlist
AKLI | $0.248 3.77% 4.02% 150K

| Email alert Add to watchlist
PTCHF | $2.64 1.15% 19.97% 0

n/a

| Email alert Add to watchlist
year for results

Vor Bio to Participate in Upcoming Investor Conferences
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
VOR | $1.74 -7.45% -7.74% 290K

| -21.97% | O: 8.52% H: 0.0% C: -9.09%

Vor Bio to Participate in Upcoming Investor Conferences - April 1, 2024
Published: 2024-04-01 (Crawled : 18:00) - biospace.com/
VOR | $1.74 -7.45% -7.74% 290K

| -21.97% | O: 8.52% H: 0.0% C: -9.09%

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
VOR | $1.74 -7.45% -7.74% 290K

| -3.33% | O: 2.78% H: 11.35% C: 5.95%
company year update financial results

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
VOR | $1.74 -7.45% -7.74% 290K

| -20.55% | O: -0.46% H: 1.83% C: -1.83%
nasdaq grant

Vor Bio to Participate in Upcoming Investor Conferences
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
VOR | $1.74 -7.45% -7.74% 290K

| -23.35% | O: 2.64% H: 2.15% C: -1.29%

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
VOR | $1.74 -7.45% -7.74% 290K

| -25.0% | O: 1.29% H: 2.13% C: -2.55%
conference life sciences

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-02 (Crawled : 21:00) - globenewswire.com
VOR | $1.74 -7.45% -7.74% 290K

| Email alert Add to watchlist
nasdaq grant

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
Published: 2024-01-17 (Crawled : 21:00) - globenewswire.com
VOR | $1.74 -7.45% -7.74% 290K

| -24.35% | O: 0.43% H: 9.09% C: 6.93%
vcar33 first update aml

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-21 (Crawled : 21:00) - globenewswire.com
VOR | $1.74 -7.45% -7.74% 290K

| -19.07% | O: 0.47% H: 4.17% C: -8.8%
nasdaq grant

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001415889-24-002104	4	2024-02-01	2024-01-29	Buy	A	125000	125000
0001415889-24-002104	4	2024-02-01	2024-01-29	Buy	A	62500	114033
0001415889-24-002101	4	2024-02-01	2024-01-29	Buy	A	107500	107500
0001415889-24-002101	4	2024-02-01	2024-01-29	Buy	A	53750	187702
0001415889-24-002098	4	2024-02-01	2024-01-29	Buy	A	470000	470000
0001415889-24-002098	4	2024-02-01	2024-01-29	Buy	A	150000	830925
0001415889-24-002096	4	2024-02-01	2024-01-29	Buy	A	100000	100000
0001415889-24-002096	4	2024-02-01	2024-01-29	Buy	A	50000	198449